Department of Pharmacy, School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India.
Indian J Pharmacol. 2010 Dec;42(6):338-44. doi: 10.4103/0253-7613.71887.
Tuberculosis (TB) is a leading chronic bacterial infection. Despite potentially curative pharmacotherapies being available for over 50 years, the length of the treatment and the pill burden can hamper patient lifestyle. Low compliance and adherence to administration schedules remain the main reasons for therapeutic failure and contribute to the development of multidrug-resistant strains. The design of novel antibiotics attempts to overcome drug resistance, to shorten the treatment course, and to reduce drug interactions. In this framework, nanotechnology appears as one of the promising approaches for the development of more effective medicines. The present review thoroughly overviews the development of novel microparticulate, encapsulation, and various other carrier-based drug delivery systems for incorporating the principal anti-TB agents. Drug delivery systems have been designed that either target the site of TB or reduce the dosing frequency with the aim of improving patient healthcare.
结核病（TB）是一种主要的慢性细菌性感染。尽管有 50 多年的潜在治愈性药物治疗，但治疗时间和药物负担可能会影响患者的生活方式。低依从性和不遵守给药时间表仍然是治疗失败的主要原因，并导致多药耐药株的发展。新型抗生素的设计旨在克服耐药性，缩短治疗过程，并减少药物相互作用。在这一框架下，纳米技术似乎是开发更有效药物的有前途的方法之一。本综述全面概述了新型微粒、包封和各种其他基于载体的药物传递系统的开发，用于包含主要的抗结核药物。已经设计了药物传递系统，这些系统要么针对结核病的部位，要么减少给药频率，旨在改善患者的医疗保健。
